MedTech Long '25: Cancer Diagnostics, Platforms & Care (view performance)

High-performing operators in this theme are expected to continue aggressive hiring in commercial roles, including field sales, medical affairs, and marketing, particularly to drive adoption of new diagnostic tests like multi-cancer early detection (MCED) and minimal residual disease (MRD) assays. Companies like GRAIL and Guardant Health have recently expanded their sales forces, and Personalis is building out its commercial team alongside Tempus AI. We should also anticipate continued investment in R&D and AI-focused talent to maintain technological leadership and develop next-generation platforms. Increased hiring in lab operations and capacity expansion roles would signal strong test volume growth. Confirmation of theme execution would be indicated by sustained growth in sales and medical liaison positions, especially in new geographic markets or for new reimbursed indications. Conversely, a slowdown in commercial hiring, hiring freezes, or significant layoffs, particularly in core product areas, would warn of market adoption challenges, reimbursement hurdles, or broader financial deterioration.

Several second-order trends are emerging within the Cancer Diagnostics, Platforms & Care theme. Firstly, the **deep integration of AI and machine learning** is becoming a critical differentiator, moving beyond mere data analysis to powering entire diagnostic platforms (e.g., Guardant Health's InfinityAI and Smart Platform) and informing drug discovery. This suggests a future where diagnostic accuracy and speed are increasingly AI-dependent. Secondly, **strategic consolidation and partnerships** are accelerating, exemplified by Personalis's acquisition by Tempus AI and GRAIL's international collaboration with Samsung. This trend highlights the need for companies to leverage complementary strengths in technology, market access, and data to scale effectively. Thirdly, the **battle for reimbursement and guideline inclusion** remains paramount, with companies intensely focused on securing FDA approvals, MolDx coverage, and endorsements from bodies like the American Cancer Society. This underscores that clinical utility must be unequivocally translated into economic value for widespread adoption. Lastly, there's a growing narrative around **longitudinal cancer monitoring and recurrence detection** through highly sensitive liquid biopsies, shifting the focus from single-point diagnosis to continuous, personalized patient management. This is driving innovation in minimal residual disease (MRD) testing and multi-cancer early detection, aiming to catch cancer earlier and track treatment response more effectively.